Eli Lilly’s multibillion-dollar acquisition of a company developing experimental psychedelic therapies marks the largest investment yet by a drugmaker in psychedelic medicine as a treatment for depression, according to a report from The Defender [1]. The purchase is part of a broader trend, with analysts describing the movement as the beginning of a “psychedelic buyout spree” [2]. Patients increasingly seek alternatives to conventional antidepressants amid concerns about limited efficacy and side effects, officials said. Data shows that one in six Americans now take psychiatric medications, and prescription drug use has reached record highs [3].
The U.S. Food and Drug Administration has granted breakthrough therapy designation to several psychedelic compounds, though the agency recently rejected MDMA-assisted therapy for post-traumatic stress disorder following allegations of scientific misconduct in clinical trials [4]. Despite that setback, developers continue to pursue regulatory approval for compounds including psilocybin and ibogaine, according to company disclosures.
Read Full Article: https://www.naturalnews.com/2026-07-30-pharma-eyes-psychedelics-market-patients-seek-depression-treatments.html
